To the best of our knowledge, no previous study has examined the relationship between methylation of the SEPT9, IGFBP3, TWIST1, GAS7, ALX4, and miR137 genes with prognosis in patients with CRC, as well as the ability of these biomarkers to predict response to 5-FU-based adjuvant chemotherapy. The gene discussed is GAS7; the disease is colorectal carcinoma.